The tweet was deleted by the author.
But we saved everything 🙂.
Esperion Therapeutics has been recognized in the Health Care and Life Sciences category of the Financial Times Americas’ Fastest Growing Companies list for 2026. The company achieved a ranking of 88 out of 300 firms spanning multiple industries.
This inclusion reflects Esperion Therapeutics' strong performance and growth trajectory within the health care sector as measured by the Financial Times. The list highlights companies demonstrating significant expansion and leadership in their respective fields.
Earlier this year, Esperion Therapeutics presented new analyses from its CLEAR Outcomes trial at the ACC 2026 annual session in cardiology, according to company disclosures. The firm also unveiled key data on its cholesterol treatment NEXLETOL from the same study at the event, as reported in recent releases. These scientific updates spotlight the company's ongoing developments within the cardiovascular sector.